Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature
暂无分享,去创建一个
Tomoko Tadokoro | A. Morishita | Koji Fujita | Shima Mimura | K. Oura | J. Tani | H. Kobara | Mai Nakahara | Kei Takuma | Tsutomu Masaki
[1] J. Marin,et al. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma , 2020, Cancers.
[2] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[3] M. Kudo. Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma , 2019, Liver Cancer.
[4] Gisela Schwab,et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.
[5] R. Weinberg,et al. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities , 2018, Frontiers of Medicine.
[6] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[7] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[8] S. Barni,et al. Clinical development of mTor inhibitors for renal cancer , 2017, Expert opinion on investigational drugs.
[9] M. Kudo,et al. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis , 2017, Digestive Diseases.
[10] N. McGranahan,et al. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.
[11] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[12] M. Kudo,et al. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan , 2015, Digestive Diseases.
[13] Masao Iwata,et al. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.
[14] K. Nishio,et al. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib , 2014, BMC Cancer.
[15] C. Bartolozzi,et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma , 2014, British Journal of Cancer.
[16] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[17] S. J. Henley,et al. Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States , 2014, The American Journal of Gastroenterology.
[18] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[19] F. Nevens,et al. A Randomized Phase II Study of Drug-Eluting Beads versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma , 2011, Oncology Research and Treatment.
[20] Matthew D. Ringel,et al. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors , 2010, Molecular and Cellular Endocrinology.
[21] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[22] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[23] J. Bruix,et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.
[24] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[25] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[26] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.